openPR Logo
Press release

Researchers say Diclofenac may cause heart problems

09-18-2006 12:01 PM CET | Health & Medicine

Press release from: The Rasansky Law Firm

/ PR Agency: Page One
After over 30 years of use, researchers found that the pain medication Diclofenac causes heart problems. The new data indicates that people who suffer from high blood pressure or heart disease should avoid the drug.

In a new analysis of 23 studies, scientists found that the Diclofenac (also called "Cataflam" and "Voltaren") increased users' chance of heart attack by 40 percent.

The Journal of the American Medical Association released the study findings because of their important cardiac health implications. Sold for over 30 years, Diclofenac is a minor prescription drug in the United States but popular and easily obtained in other countries.

Researchers are firm about getting Diclofenac off the market. Even though the possibility that it will cause heart problems is low, its benefits are few when compared to other similar drugs. The FDA has responded to the diclofenac heart trouble findings, stating that the organization does not deem the new diclofenac data conclusive.

The study included an examination of 7 other pain drugs, including Naproxen (Aleve) and Celebrex. Both drugs fared better than diclofenac, which was the only one shown to pose a risk to cardiovascular health.

The report investigates the effects of a group of drugs called NSAIDs, nonsteroidal anti-inflammatory drugs.

The approximate number of people using NSAIDs is 30 million. Of those, very few suffer from heart problems.

Vioxx, belonging to a subset of NSAIDs called Cox-2 inhibitors, had to be removed from the market because it was found to cause heart problems similar to Diclofenac's. The Cox-2 inhibitors are supposedly easier on the stomach than some previously developed NSAID such as ibuprofen and naproxen.

The Cox-2 drugs did well commercially but Merck & Co. had to take Vioxx off the market when they learned that some patients were incurring heart problems.

The Rasansky Law Firm
2525 McKinnon Suite 625 Dallas, TX 75201
1-800-288-6763
http://www.texasinjuryattorney.com

At The Rasansky Law Firm, you will find experienced, aggressive Attorneys that are ready to provide the resources needed to win large, complex lawsuits. The Rasansky Law Firm continues to aggressively represent nationwide clients in cases involving, but not limited to: Absestos, Auto Accidents, Brain Injuries, Cerebral Palsy, Lasik, Medical Malpractice, Mesothelioma, Personal Injury, Paralysis, Nursing Home Abuse, Unpaid Overtime and Wrongful Death. The Rasansky Law Firm may be contacted at http://www.texasinjuryattorney.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Researchers say Diclofenac may cause heart problems here

News-ID: 11305 • Views:

More Releases from The Rasansky Law Firm

Rasansky Law Firm’s Robert Wolf Named to 2011 Texas Rising Stars List
DALLAS – Personal injury attorney Robert Wolf of Dallas’ Rasansky Law Firm has earned a spot on the 2011 Texas Rising Stars list of the state’s top young lawyers. Mr. Wolf, who has practiced at the Rasansky Law Firm since 2001, has tried numerous cases to verdict during his legal career, including one notable matter where the jury sent a note asking the court: “Is there an amount we could award
Dallas Attorney Jeff Rasansky Recognized as One of Texas’ Top Lawyers
DALLAS – Dallas plaintiffs’ personal injury attorney Jeff Rasansky has earned a spot among state’s top lawyers in the 2009 Texas Super Lawyers list published in Texas Monthly magazine. Mr. Rasansky, founder of Dallas’ The Rasansky Law Firm, has earned this recognition each year since the Texas Super Lawyers list was first published in 2003. The annual Texas Super Lawyers listing highlights the state’s top attorneys as determined by a statewide
Personal Injury Attorney Jeff Rasansky Highlighted Among Dallas’ Best Lawyers
DALLAS – Dallas personal injury attorney Jeff Rasansky, founder of the Rasansky Law Firm, is featured in D Magazine’s recently released list of “The Best Lawyers in Dallas.” Mr. Rasansky is one of only 15 attorneys in the city to earn recognition based on their work in personal injury litigation. To compile “The Best Lawyers in Dallas” listing, D Magazine asked lawyers to nominate attorneys in their same practice area
Dallas Jury Returns $911,000 Verdict In DWI Vehicle Accident Case
DALLAS – Jurors in Judge Carlos Cortez’ 44th District Court in Dallas have awarded $911,000 to a Dallas man who was severely injured in a December 2004 auto collision caused by another driver who was under the influence of alcohol and narcotics. Attorney Jeff Rasansky of Dallas’ Rasansky Law Firm and firm attorney Robert Wolf represented James P. Bar in the lawsuit against defendant Brandon Robert Botts. Mr. Bar suffered life-threatening neck

All 5 Releases


More Releases for Diclofenac

Global Diclofenac Patches Market 2020|, Acorda Therapeutics, Endo International, …
LOS ANGELES, United States: Considering the growth factors of pharma and Healthcare industry, QY Research has recently published a report, titled “Global Diclofenac Patches Market Research Report 2020". The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Diclofenac Patches market is relied upon to develop generously and succeed in volume
Diclofenac Market to Perceive Substantial Growth During 2017 - 2023
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that is mainly employed to treat mild-to-moderate pain & reduces pain, inflammation, swelling, and stiffness. This drug is applicable for inflammatory disorders such as arthritis, rheumatoid arthritis, dermatomyositis, osteoarthritis, dental pain, spondylarthritis, and gout attacks. The major factors that contribute to the growth of the diclofenac market include increasing prevalence of autoimmune and respiratory conditions such as arthritis & dental pain, increasing adoption of
Diclofenac Market to Witness Fastest Growth by 2023
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that is mainly employed to treat mild-to-moderate pain & reduces pain, inflammation, swelling, and stiffness. This drug is applicable for inflammatory disorders such as arthritis, rheumatoid arthritis, dermatomyositis, osteoarthritis, dental pain, spondylarthritis, and gout attacks. Get Access to TOC / Sample Report @ https://www.alliedmarketresearch.com/request-toc-and-sample/3809 The major factors that contribute to the growth of the diclofenac market include increasing prevalence of autoimmune and respiratory conditions such
Diclofenac Diethylammonium Market Strategy 2018 Future Industry Analysis 2023
Future Market Reports on Global Diclofenac Diethylammonium 2018 Research Report presents a professional and complete analysis of Global Diclofenac Diethylammonium Market on the current market situation. The Global Diclofenac Diethylammonium Market 2018 report includes Diclofenac Diethylammonium market Revenue, market Share, Diclofenac Diethylammonium industry volume, market Trends, Growth aspects. It analyses the important factors of the Diclofenac Diethylammonium market based on present industry situations, Diclofenac Diethylammonium market demands, business strategies utilized
Diclofenac Patches Market trend, outlook 2026
Diclofenac is nonsteroidal anti-inflammatory drug (NSAID), which works in reducing hormones that cause inflammation and pain in the body. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used therapeutic class of analgesic compounds, indicated to use in relieving post extraction pain. Diclofenac sodium is a commonly prescribed NSAID, which exhibits anti-inflammatory, analgesic and anti-pyretic activity. Diclofenac transdermal patches are used to get temporary relief of minor aches and pains of
Diclofenac Patches Market Segmentation Application, Technology & Market Analysis …
Worldwide Market Reports added Latest Research Report titled " Global Diclofenac Patches Market Research Report 2017 " to its Large Report database. In this report, the global Diclofenac Patches market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production,